Welcome to our dedicated page for Immunitybio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on Immunitybio stock.
ImmunityBio, Inc. (NASDAQ: IBRX) generates frequent news as a commercial-stage biotechnology company centered on IL‑15–based immunotherapies and cell therapies. Its updates often highlight clinical data, regulatory milestones, and commercial performance for ANKTIVA, an IL‑15 receptor agonist fusion complex that the company describes as a key component of its BioShield platform.
News coverage commonly focuses on bladder cancer and non‑small cell lung cancer (NSCLC). For non‑muscle invasive bladder cancer, ImmunityBio reports results from the QUILT‑3.032 trial of ANKTIVA plus BCG in BCG‑unresponsive disease, including data on disease‑specific survival, progression‑free survival, and cystectomy avoidance. For NSCLC, press releases describe findings from QUILT‑2.023 and QUILT‑3.055, where ANKTIVA combined with checkpoint inhibitors has been associated with immune restoration, measured by absolute lymphocyte count, and linked to survival outcomes in checkpoint‑experienced patients.
Regulatory developments are another major news theme. Recent announcements include a conditional marketing authorization recommendation from the European Medicines Agency for ANKTIVA plus BCG in BCG‑unresponsive NMIBC CIS, as well as Saudi Food and Drug Authority approvals for ANKTIVA plus BCG in NMIBC CIS and for ANKTIVA in combination with checkpoint inhibitors in metastatic NSCLC, including the first approval for subcutaneous administration. These items illustrate how ImmunityBio’s news flow tracks the global expansion of ANKTIVA‑based regimens.
Investors and observers can also expect news on financial results and product revenue, particularly net product revenue and unit growth for ANKTIVA, along with cash position and capital‑raising activities disclosed in earnings releases and related Form 8‑K filings. Additional stories cover early data in glioblastoma using ANKTIVA plus NK cell therapy and the Optune Gio device, initiatives in non‑Hodgkin lymphoma and other cancers, and participation in forums such as the U.S.–Saudi Biotech Alliance Summit.
By following ImmunityBio’s news page, readers can track clinical trial progress, new approvals, and commercial trends that shape the outlook for IBRX and its IL‑15–based immunotherapy programs.
ImmunityBio, Inc. (NASDAQ: IBRX) announced the development of a novel hAd5 ACE2 Decoy therapeutic vaccine targeting SARS-CoV-2, including key mutations E484K and N501Y. Presented at the 28th CROI, the findings highlight the vaccine’s high binding affinity to these variants. The ACE2 Decoy aims to compete with natural ACE2 receptors in the respiratory tract to trap the virus and prevent infection. Given the rapid emergence of COVID-19 variants, this advancement is crucial for treatment and prevention efforts, warranting further clinical development.
ImmunityBio (NASDAQ: IBRX) has commenced trading as a large-cap company with approximately 398 million fully diluted shares following its merger with NantKwest. The combined entity is now listed on the Global Select Market of Nasdaq. ImmunityBio specializes in late-stage immunotherapy, focusing on innovative therapies for cancer and infectious diseases, backed by a pipeline of over 40 clinical trials in development across 19 indications. Its lead product, Anktiva™, has received favorable FDA designations for certain bladder cancer treatments.